Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?

被引：2
|
作者：
Carney, Dennis A. [1 ]
Seymour, John F. [1 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne 3002, Australia
来源：
LEUKEMIA & LYMPHOMA | 2010年 / 51卷 / 11期
关键词：
ACUTE MYELOID-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; STEM-CELL MOBILIZATION; NON-HODGKINS-LYMPHOMA; CYCLOPHOSPHAMIDE; MITOXANTRONE; CHLORAMBUCIL; RITUXIMAB; CANCER;
D O I：
10.3109/10428194.2010.514084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1957 / 1959
页数：3
相关论文
共 50 条
  • [31] High incidence of therapy-related myelodysplasia and acute myeloid leukaemia (tMDS/tAML) following treatment with fludarabine and cyclophosphamide for low grade lymphoproliferative disorders
    Bowcock, SJ
    Rassam, SMB
    Lim, ZY
    Ward, SM
    Mufti, GJ
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 54 - 54
  • [32] Are there real benefits of hypomethylating agents for therapy-related myeloid neoplasms?
    Breccia, Massimo
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2013, 37 (05) : 485 - 486
  • [33] Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
    Mithun Vinod Shah
    Abhishek A. Mangaonkar
    Kebede H. Begna
    Hassan B. Alkhateeb
    Patricia Greipp
    Ahmad Nanaa
    Michelle A. Elliott
    William J. Hogan
    Mark R. Litzow
    Kristen McCullough
    Ayalew Tefferi
    Naseema Gangat
    Mrinal M. Patnaik
    Aref Al-Kali
    Rong He
    Dong Chen
    Blood Cancer Journal, 12
  • [34] Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
    Shah, Mithun Vinod
    Mangaonkar, Abhishek A.
    Begna, Kebede H.
    Alkhateeb, Hassan B.
    Greipp, Patricia
    Nanaa, Ahmad
    Elliott, Michelle A.
    Hogan, William J.
    Litzow, Mark R.
    McCullough, Kristen
    Tefferi, Ayalew
    Gangat, Naseema
    Patnaik, Mrinal M.
    Al-Kali, Aref
    He, Rong
    Chen, Dong
    BLOOD CANCER JOURNAL, 2022, 12 (07)
  • [35] Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm
    Bataller, Alex
    Gener-Ricos, Georgina
    Almanza-Huante, Emmanuel
    Chien, Kelly S.
    Urrutia, Samuel
    Bazinet, Alexandre
    Rodriguez-Sevilla, Juan Jose
    Hammond, Danielle
    Sasaki, Koji
    Takahashi, Koichi
    Dinardo, Courtney D.
    Ravandi, Farhad
    Borthakur, Gautam
    Kadia, Tapan M.
    Kanagal-Shamanna, Rashmi
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    BLOOD ADVANCES, 2024, 8 (11) : 2695 - 2706
  • [36] Limits and Benefits of Non-Controlled Therapy-Related Observations
    Tuerp, Jens C.
    Sedivy, Roland
    Schlaeppi, Marc R.
    Spranger, Heinz
    Endler, Christian
    FORSCHENDE KOMPLEMENTARMEDIZIN, 2010, 17 (06): : 336 - 342
  • [37] Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer
    Yagita, M
    Ieki, Y
    Onishi, R
    Huang, CL
    Adachi, M
    Horiike, S
    Konaka, Y
    Taki, T
    Miyake, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1998, 13 (01) : 91 - 96
  • [38] CHROMOSOME-ABERRATIONS AND PROGNOSTIC FACTORS IN THERAPY-RELATED MYELODYSPLASIA AND ACUTE NONLYMPHOCYTIC LEUKEMIA
    PEDERSENBJERGAARD, J
    PHILIP, P
    LARSEN, SO
    JENSEN, G
    BYRSTING, K
    BLOOD, 1990, 76 (06) : 1083 - 1091
  • [39] THERAPY-RELATED LEUKEMIA
    MICHELS, SD
    MCKENNA, RW
    ARTHUR, D
    BRUNNING, RD
    LABORATORY INVESTIGATION, 1984, 50 (01) : A40 - A41
  • [40] BRAF and MEK inhibitor combination therapy-related eye AEs
    Reactions Weekly, 2023, 1948 (1) : 10 - 10
12345